Live federal data · NADAC weekly · Part D CY24

Ruxolitinib Dasatinib

Ruxolitinib vs Dasatinib — $4.23B of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Kinase Inhibitor

Ruxolitinib

Brand: JAKAFI

First FDA approval: 2011-11-16

Kinase Inhibitor

Dasatinib

Brand: PHYRAGO

First FDA approval: 2006-06-27

Lowest NADACAcquisition cost floor across all NDCs

$34.02Per unit

$26.32Per unit

Average NADACAcross all dosage forms and strengths

$34.02Up to $34.02

$82.80Up to $591.18

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

848 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$3.38BFull year

$850.6MFull year

Part D claims (CY24)Total fills, all strengths

280K62K beneficiaries

75K16K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$12,050Per claim, all NDCs

$11,337Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1642Substantial friction

1992Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes8 manufacturers